 "Illustration: Ajay Mohanty")
Divi’s Laboratories quarter results: After a 49 per cent y-o-y growth in the June quarter and a 21 per cent uptick in the September quarter, Divi’s Laboratories continued its strong growth run in the December quarter. The country’s second largest pharma company by market capitalisation posted a 22 per cent growth in Q3 led by the generics segment which accounts for 60 per cent of its revenues.
In addition to top line growth, which has over the past three quarters benefitted from supply constraints, higher outsourcing trend and the China+1 strategy, margins too, have remained at elevated levels. The company
